Dataset from Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy

Primary Objective:

To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to
topotecan in participants with sensitive or resistant/refractory small cell lung cancer
following a first line platinum based chemotherapy.

Secondary Objectives:

- To assess disease progression free rate at 12 weeks

- To assess Response Rate (Response Evaluation Criteria in Solid Tumor [RECIST] 1.1) and
duration of response

- To assess Overall Survival (OS)

- To assess the Safety (National Cancer Institute - Common Toxicity Criteria [NCI-CTC]
version 4.03)

- To assess the Health-Related Quality of Life (HRQoL)